-86%

est. 2Y upside i

HealthcareSeries A

The Human Diagnosis Project.

Rank

#4225

Sector

Healthtech

Est. Liquidity

~4Y

Data Quality

Data: Low

Human Dx presents a high-risk equity opportunity with a negative expected upside.

Last updated: March 10, 2026

Bull (10%)+250%

Human Dx successfully scales its eConsult system and global network, demonstrating superior diagnostic accuracy through its human-AI collective model. This leads to a strategic acquisition by a large healthcare or tech company, valuing the company at $70M-$100M, leveraging its unique data and partnerships.

Base (25%)+25%

Human Dx continues to operate as a niche player, maintaining its partnerships and community but struggling to achieve significant commercial scale against well-funded incumbents. A small strategic acquisition or continued grant-based operation provides a modest return, valuing the company at around $25M.

Bear (65%)-85%

Intense competition from dominant incumbents like Google and established healthcare IT players, coupled with limited funding and slow commercial adoption, prevents Human Dx from scaling. The company faces a distressed sale or winds down operations, wiping out most common stock value given the preference stack.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Investors hold $2.8M in liquidation preferences. In an exit at or below an estimated $20M valuation, common stock holders would see significantly reduced returns or nothing after preferences are paid.

Dilution Risk

high

With only $2.8M raised since 2012/2013, significant future funding rounds would be needed to scale, leading to substantial dilution for existing equity holders.

Secondary Liquidity

limited

A private secondary transaction was noted in March 2023, but there is no indication of an active secondary market for Human Dx equity.

Questions to Ask at the Interview

Strategic questions based on Human Dx's data — designed to show you've done your homework.

  • 1

    “Given the strong presence of large tech companies like Google and OpenAI in AI, how does Human Dx differentiate its 'collective intelligence with machine learning' approach to maintain a competitive edge and secure market share, especially in light of the 'EHR moat' discussed in recent digital health reports?”

  • 2

    “With $2.8M in total funding since its founding, what is the company's long-term financial strategy for scaling its eConsult system and global network, and what are the key revenue milestones for the next 2-3 years to attract further investment or achieve sustainable operations?”

  • 3

    “Considering the 'formerly VC-backed' status and the 2023 secondary transaction, what is the anticipated timeline for a liquidity event for employees, and what are the company's plans for future funding rounds or secondary liquidity opportunities to de-risk employee equity?”

Community

Valuation Sentiment

Our model estimates -86% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.